New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.

Dow Jones stock MerckMRK and eight other bellwether pharmaceutical companies struck drug-pricing agreements with the Trump ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few years. In the meantime, the company's performance leaves a lot to be desired.

MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

NASA opens the International Space Station for scientists and researchers, inviting them to use the benefits of microgravity for private industry research, technology demonstrations, and more. Today, ...

We recently published 12 Stocks on Jim Cramer’s Radar . Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

Merck (MRK) stock gains as BMO Capital Markets upgrades the company to Outperform citing strong portfolio moves before ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...